205 related articles for article (PubMed ID: 19934317)
1. In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.
Ugel S; Zoso A; De Santo C; Li Y; Marigo I; Zanovello P; Scarselli E; Cipriani B; Oelke M; Schneck JP; Bronte V
Cancer Res; 2009 Dec; 69(24):9376-84. PubMed ID: 19934317
[TBL] [Abstract][Full Text] [Related]
2. An Artificial Antigen-Presenting Cell Delivering 11 Immune Molecules Expands Tumor Antigen-Specific CTLs in
Zhang L; Song S; Jin X; Wan X; Shahzad KA; Pei W; Zhao C; Shen C
Cancer Immunol Res; 2019 Jul; 7(7):1188-1201. PubMed ID: 31113806
[TBL] [Abstract][Full Text] [Related]
3. In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).
Durai M; Krueger C; Ye Z; Cheng L; Mackensen A; Oelke M; Schneck JP
Cancer Immunol Immunother; 2009 Feb; 58(2):209-20. PubMed ID: 18563409
[TBL] [Abstract][Full Text] [Related]
4. CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells.
Bruns H; Bessell C; Varela JC; Haupt C; Fang J; Pasemann S; Mackensen A; Oelke M; Schneck JP; Schütz C
Clin Cancer Res; 2015 May; 21(9):2075-83. PubMed ID: 25593301
[TBL] [Abstract][Full Text] [Related]
5. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice.
Verra NC; Jorritsma A; Weijer K; Ruizendaal JJ; Voordouw A; Weder P; Hooijberg E; Schumacher TN; Haanen JB; Spits H; Luiten RM
Cancer Res; 2004 Mar; 64(6):2153-61. PubMed ID: 15026357
[TBL] [Abstract][Full Text] [Related]
6. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
[TBL] [Abstract][Full Text] [Related]
7. HLA-Ig based artificial antigen presenting cells for efficient ex vivo expansion of human CTL.
Chiu YL; Schneck JP; Oelke M
J Vis Exp; 2011 Apr; (50):. PubMed ID: 21505415
[TBL] [Abstract][Full Text] [Related]
8. Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy.
Hamieh M; Chatillon JF; Dupel E; Bayeux F; Fauquembergue E; Maby P; Drouet A; Duval-Modeste AB; Adriouch S; Boyer O; Latouche JB
Front Immunol; 2021; 12():674276. PubMed ID: 34566953
[TBL] [Abstract][Full Text] [Related]
9. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
Dupont J; Latouche JB; Ma C; Sadelain M
Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T lymphocytes generated by short-term in vitro TCR stimulation in the presence of IL-4 are therapeutically effective against B16 melanoma.
Chang ML; Chen YT; Su YC; Kung JT
J Biomed Sci; 2003; 10(6 Pt 1):644-50. PubMed ID: 14576467
[TBL] [Abstract][Full Text] [Related]
11. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.
Alexander-Miller MA; Leggatt GR; Berzofsky JA
Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4102-7. PubMed ID: 8633023
[TBL] [Abstract][Full Text] [Related]
12. Tracking in vivo migration and distribution of antigen-specific cytotoxic T lymphocytes by 5,6-carboxyfluorescein diacetate succinimidyl ester staining during cancer immunotherapy.
Xu WL; Li SL; Wen M; Wen JY; Han J; Zhang HZ; Gao F; Cai JH
Chin Med J (Engl); 2013 Aug; 126(16):3019-25. PubMed ID: 23981604
[TBL] [Abstract][Full Text] [Related]
13. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
Butler MO; Lee JS; Ansén S; Neuberg D; Hodi FS; Murray AP; Drury L; Berezovskaya A; Mulligan RC; Nadler LM; Hirano N
Clin Cancer Res; 2007 Mar; 13(6):1857-67. PubMed ID: 17363542
[TBL] [Abstract][Full Text] [Related]
14. Decreased tumor surveillance after adoptive T-cell therapy.
Matter M; Pavelic V; Pinschewer DD; Mumprecht S; Eschli B; Giroglou T; von Laer D; Ochsenbein AF
Cancer Res; 2007 Aug; 67(15):7467-76. PubMed ID: 17671217
[TBL] [Abstract][Full Text] [Related]
15. Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response.
Lu X; Jiang X; Liu R; Zhao H; Liang Z
Cancer Lett; 2008 Nov; 271(1):129-39. PubMed ID: 18621475
[TBL] [Abstract][Full Text] [Related]
16. Artificial antigen-presenting cells plus IL-15 and IL-21 efficiently induce melanoma-specific cytotoxic CD8+ CD28+ T lymphocyte responses.
Yu X; He J; Mongkhoune S; Peng Y; Xie Y; Su J; Zhou SF; Xie XX; Luo GR; Fang Y; Li X; Li X; Zhou N; Zhao YX; Lu XL
Asian Pac J Trop Med; 2013 Jun; 6(6):467-72. PubMed ID: 23711708
[TBL] [Abstract][Full Text] [Related]
17. Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity.
Tucker CG; Mitchell JS; Martinov T; Burbach BJ; Beura LK; Wilson JC; Dwyer AJ; Singh LM; Mescher MF; Fife BT
J Immunol; 2020 Sep; 205(5):1449-1460. PubMed ID: 32737148
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.
Nishimura F; Dusak JE; Eguchi J; Zhu X; Gambotto A; Storkus WJ; Okada H
Cancer Res; 2006 Apr; 66(8):4478-87. PubMed ID: 16618775
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.
Lou Y; Wang G; Lizée G; Kim GJ; Finkelstein SE; Feng C; Restifo NP; Hwu P
Cancer Res; 2004 Sep; 64(18):6783-90. PubMed ID: 15374997
[TBL] [Abstract][Full Text] [Related]
20. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K
Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
